These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 35122335)

  • 41. Adverse events of Dupilumab in adults with moderate-to-severe atopic dermatitis: A meta-analysis.
    Ou Z; Chen C; Chen A; Yang Y; Zhou W
    Int Immunopharmacol; 2018 Jan; 54():303-310. PubMed ID: 29182975
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ocular surface disease associated with dupilumab treatment for atopic diseases.
    Utine CA; Li G; Asbell P; Pflugfelder S; Akpek E
    Ocul Surf; 2021 Jan; 19():151-156. PubMed ID: 32439390
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Two cases of dupilumab-associated conjunctivitis with high expression of IL-8 mRNA on the ocular surface: a case report.
    Adachi R; Shoji J; Hirota A; Tomioka A; Tonozuka Y; Inada N; Yamagami S
    Allergy Asthma Clin Immunol; 2022 Oct; 18(1):89. PubMed ID: 36184619
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of Dupilumab on Laboratory Parameters in Adolescents with Atopic Dermatitis: Results from a Randomized, Placebo-Controlled, Phase 3 Clinical Trial.
    Siegfried EC; Bieber T; Simpson EL; Paller AS; Beck LA; Boguniewicz M; Schneider LC; Khokhar FA; Chen Z; Prescilla R; Mina-Osorio P; Bansal A
    Am J Clin Dermatol; 2021 Mar; 22(2):243-255. PubMed ID: 33655423
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Efficacy of dupilumab in real practice in the treatment of severe forms of asthma and atopic dermatitis (comparative retrospective study)].
    Fomina DS; Fedosenko SV; Bobrikova EN; Chernov AA; Mukhina OA; Lebedkina MS; Karaulov AV; Nurtazina AY; Lysenko MA
    Ter Arkh; 2023 Sep; 95(7):568-573. PubMed ID: 38159007
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.
    Bieber T; Simpson EL; Silverberg JI; Thaçi D; Paul C; Pink AE; Kataoka Y; Chu CY; DiBonaventura M; Rojo R; Antinew J; Ionita I; Sinclair R; Forman S; Zdybski J; Biswas P; Malhotra B; Zhang F; Valdez H;
    N Engl J Med; 2021 Mar; 384(12):1101-1112. PubMed ID: 33761207
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis: A Randomized Clinical Trial.
    Worm M; Simpson EL; Thaçi D; Bissonnette R; Lacour JP; Beissert S; Kawashima M; Ferrándiz C; Smith CH; Beck LA; Chan KC; Chen Z; Akinlade B; Hultsch T; Staudinger H; Gadkari A; Eckert L; Davis JD; Rajadhyaksha M; Graham NMH; Pirozzi G; Stahl N; Yancopoulos GD; Ardeleanu M
    JAMA Dermatol; 2020 Feb; 156(2):131-143. PubMed ID: 31876900
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
    Beck LA; Thaçi D; Deleuran M; Blauvelt A; Bissonnette R; de Bruin-Weller M; Hide M; Sher L; Hussain I; Chen Z; Khokhar FA; Beazley B; Ruddy M; Patel N; Graham NMH; Ardeleanu M; Shumel B
    Am J Clin Dermatol; 2020 Aug; 21(4):567-577. PubMed ID: 32557382
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.
    Bachert C; Han JK; Desrosiers M; Hellings PW; Amin N; Lee SE; Mullol J; Greos LS; Bosso JV; Laidlaw TM; Cervin AU; Maspero JF; Hopkins C; Olze H; Canonica GW; Paggiaro P; Cho SH; Fokkens WJ; Fujieda S; Zhang M; Lu X; Fan C; Draikiwicz S; Kamat SA; Khan A; Pirozzi G; Patel N; Graham NMH; Ruddy M; Staudinger H; Weinreich D; Stahl N; Yancopoulos GD; Mannent LP
    Lancet; 2019 Nov; 394(10209):1638-1650. PubMed ID: 31543428
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis.
    Hirano I; Dellon ES; Hamilton JD; Collins MH; Peterson K; Chehade M; Schoepfer AM; Safroneeva E; Rothenberg ME; Falk GW; Assouline-Dayan Y; Zhao Q; Chen Z; Swanson BN; Pirozzi G; Mannent L; Graham NMH; Akinlade B; Stahl N; Yancopoulos GD; Radin A
    Gastroenterology; 2020 Jan; 158(1):111-122.e10. PubMed ID: 31593702
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety of dupilumab in a 5-month-old infant with severe atopic dermatitis.
    Havele SA; Khurana MC; McMahon P; Murthy AS; Perman MJ; Treat JR
    Pediatr Dermatol; 2022 Mar; 39(2):291-294. PubMed ID: 35434859
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term real-world experience of the side effects of dupilumab in 128 patients with atopic dermatitis and related conditions aged 6 years and above: Retrospective chart analysis from a single tertiary care center.
    Parmar NV; Abdula MA; Al Falasi A; Krishna CV
    Dermatol Ther; 2022 May; 35(5):e15415. PubMed ID: 35238115
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluation of adult patients with atopic dermatitis treated with dupilumab: A single-center real-life experience.
    Su Küçük Ö; Güneş B; Taşlidere N; Işik BG; Akaslan TÇ; Özgen FP; Bahali AG
    J Cosmet Dermatol; 2022 Oct; 21(10):4781-4787. PubMed ID: 35038377
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dupilumab-associated ocular surface disease: presentation, management and long-term sequelae.
    Popiela MZ; Barbara R; Turnbull AMJ; Corden E; Martinez-Falero BS; O'Driscoll D; Ardern-Jones MR; Hossain PN
    Eye (Lond); 2021 Dec; 35(12):3277-3284. PubMed ID: 33504973
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Multicenter prospective observational study of dupilumab-induced ocular events in atopic dermatitis patients.
    Costedoat I; Wallaert M; Gaultier A; Vasseur R; Vanhaecke C; Viguier M; Cordelette C; Denoyer A; Ferrier le Bouëdec MC; Coutu A; Lamiaux M; Tran THC; Lacour JP; Elmaleh V; Tetart F; Gueudry J; Tauber M; Giordano-Labadie F; Cassagne M; Nosbaum A; Ouilhon C; Jachiet M; Tadayoni R; Dezoteux F; Staumont-Salle D; Bouleau J; Labalette P; Doan S; Soria A; Mortemousque B; Seneschal J; Barbarot S;
    J Eur Acad Dermatol Venereol; 2023 May; 37(5):1056-1063. PubMed ID: 36732052
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Global influence of dupilumab on Quality of Life in a severe asthma patient with T2 multimorbidities: a case report on atopic dermatitis, chronic rhinosinusitis with nasal polyposis, and eosinophilic esophagitis.
    Colque-Bayona M; Hernández-Cano N; Tomás-Pérez M; Caballero T; Quirce S; Domínguez-Ortega J
    J Asthma; 2024 Jul; 61(7):762-765. PubMed ID: 38152869
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ocular Surface Disease in Patients With Atopic Dermatitis Treated With Dupilumab: A Prospective Case-Control Study.
    Marolo P; Ribero S; Caselgrandi P; Ghilardi A; de Sanctis U; Parisi G; Fallico M; Borrelli E; Ortoncelli M; Gelato F; Mastorino L; Tibaldi T; Roccuzzo G; Quaglino P; Reibaldi M
    Cornea; 2024 Feb; 43(2):221-227. PubMed ID: 37404010
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase 3 Trials.
    Griffiths C; de Bruin-Weller M; Deleuran M; Fargnoli MC; Staumont-Sallé D; Hong CH; Sánchez-Carazo J; Foley P; Seo SJ; Msihid J; Chen Z; Cyr SL; Rossi AB
    Dermatol Ther (Heidelb); 2021 Aug; 11(4):1357-1372. PubMed ID: 34142350
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Improvement in eosinophilic esophagitis when using dupilumab for other indications or compassionate use.
    Spergel BL; Ruffner MA; Godwin BC; Liacouras CA; Cianferoni A; Gober L; Hill DA; Brown-Whitehorn TF; Chaiboonma K; Aceves SA; Muir AM; Spergel JM
    Ann Allergy Asthma Immunol; 2022 May; 128(5):589-593. PubMed ID: 35085819
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dupilumab in the treatment of moderate-to-severe atopic dermatitis.
    Kraft M; Worm M
    Expert Rev Clin Immunol; 2017 Apr; 13(4):301-310. PubMed ID: 28165826
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.